Does Rallies show Form 4 insider transactions for IRD?

Yes. Rallies tracks IRD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IRD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IRD. It does not provide personalized investment advice.

IRD (Opus Genetics, Inc. Common Stock) Stock Analysis - Insider Trades

Opus Genetics, Inc. Common Stock (IRD) is a publicly traded Healthcare sector company. As of May 21, 2026, IRD trades at $4.59 with a market cap of $361.40M and a P/E ratio of -5.42. IRD moved +4.46% today. Year to date, IRD is +108.45%; over the trailing twelve months it is +346.68%. Its 52-week range spans $0.65 to $5.81. Analyst consensus is strong buy with an average price target of $10.58. Rallies surfaces IRD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IRD stock inside the company?

Recent IRD insider activity includes Foundation Fighting Blindness Retinal Degeneration Fund sold 1.70M, YERXA BENJAMIN R sold 7.47K, SCHACHLE JOSEPH K sold 4.70K, Zaremba Rabourn Amy sold 1.64K, and Magrath George sold 9.51K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IRD Key Metrics

Key financial metrics for IRD
Metric	Value
Price	$4.59
Market Cap	$361.40M
P/E Ratio	-5.42
EPS	$-0.80
Dividend Yield	0.00%
52-Week High	$5.81
52-Week Low	$0.65
Volume	5
Avg Volume	0
Revenue (TTM)	$14.20M
Net Income	$-49.59M
Gross Margin	0.00%

Recent IRD Insider Trades

Foundation Fighting Blindness Retinal Degeneration Fund sold 1.70M (~$7.39M) on May 18, 2026.
YERXA BENJAMIN R sold 7.47K (~$39.12K) on Apr 23, 2026.
SCHACHLE JOSEPH K sold 4.70K (~$24.52K) on Apr 23, 2026.
Zaremba Rabourn Amy sold 1.64K (~$8.54K) on Apr 23, 2026.
Magrath George sold 9.51K (~$49.65K) on Apr 23, 2026.

Latest IRD News

Opus Genetics Eyes September OPGx-BEST1 Data, Extends Runway Into 2029 — May 12, 2026
Opus Genetics Completes 5-Patient Phase 1/2 OPGx-BEST1 Cohort — May 7, 2026
Opus Genetics’ LCA5 Gene Therapy Accepted into FDA Rare Disease Evidence Program — May 4, 2026
Opus Genetics to Present OPGx-BEST1 Phase 1b/2a Data and OPGx-RHO Safety Findings — Apr 27, 2026
Opus Genetics Raises $155M Financing, Extends Cash Runway into 2029 — Apr 6, 2026

IRD Analyst Consensus

13 analysts cover IRD: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.58.

Common questions about IRD

Who is trading IRD stock inside the company?: Recent IRD insider activity includes Foundation Fighting Blindness Retinal Degeneration Fund sold 1.70M, YERXA BENJAMIN R sold 7.47K, SCHACHLE JOSEPH K sold 4.70K, Zaremba Rabourn Amy sold 1.64K, and Magrath George sold 9.51K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IRD?: Yes. Rallies tracks IRD insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IRD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IRD. It does not provide personalized investment advice.